BACKGROUND: The p75 neurotrophin receptor (p75NTR) is a critical regulator of diverse biological processes. Depending on the cellular context, p75NTR can promote trophic or degenerative signaling, which can influence a broad spectrum of pathological conditions, including neurodegenerative diseases, inflammatory/infectious conditions, and various central and peripheral nervous system injuries. These attributes of p75NTR and its widespread, frequently upregulated expression on affected cells and tissues, make it a compelling therapeutic target. Among various therapeutic targeting strategies, the first-in-class small molecule p75NTR modulator, LM11A-31, has emerged as a leading candidate and has been evaluated in 62 published preclinical studies spanning 26 distinct disease and injury models.
